Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial-Reference-Cited by-同舟云学术

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Published:2024-09 Issue:9 Volume:11 Page:e646-e658
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Della Porta Matteo Giovanni,Garcia-Manero Guillermo,Santini Valeria,Zeidan Amer M,Komrokji Rami S,Shortt Jake,Valcárcel David,Jonasova Anna,Dimicoli-Salazar Sophie,Tiong Ing Soo,Lin Chien-Chin,Li Jiahui,Zhang Jennie,Pilot Richard,Kreitz Sandra,Pozharskaya Veronika,Keeperman Karen L,Rose Shelonitda,Prebet Thomas,Lai Yinzhi,Degulys Andrius,Paolini Stefania,Cluzeau Thomas,Fenaux Pierre,Platzbecker Uwe

Funder

Bristol-Myers Squibb

National Comprehensive Cancer Network

Bristol-Myers Squibb Co Summit

Publisher

Elsevier BV

Reference28 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

2. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts;Papaemmanuil;N Engl J Med,2011

3. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis;Suragani;Nat Med,2014

4. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms;Khoury;Leukemia,2022

5. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes;de Swart;Haematologica,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes;The Lancet Haematology;2024-09